HomeNewsBusinessCompaniesIPR policy is a good move by the government: Experts

IPR policy is a good move by the government: Experts

No pharma company is taking up patent issues with the WTO as they are looking to sort out the issue through treaties, says Kewal Handa, Former MD of Pfizer.

May 13, 2016 / 22:17 IST
Story continues below Advertisement

Your browser doesn't support HTML5 video.

The Cabinet today gave its nod to the national Intellectual Property Right (IPR) policy, saying it endeavours to ring in a “Creative India; Innovative India”. Through this policy, the government aims to lay the roadmap for intellectual property (IP) in the country, recognise innovative energies, exploit synergies between all forms of IP, create awareness on benefits of IP, and enhance access to healthcare, food security and environmental protection, among others.The Department of Industrial Policy & Promotion (DIPP) will be the nodal department to co-ordinate, guide and oversee implementation and future development of IPR’s in India.Two key highlights of the policy states there will be no changes to compulsory licences issued to pharma companies. There will also be no amendments to evergreening of patents. Finance Minister Arun Jaitley anouncing the news said that IPR laws are World Trade Organisation (WTO)-compliant.  

Kewal Handa, Former MD of Pfizer, said that some of the pharma companies have already adjusted to the new reality. Evergreening of patent right is a method allegedly adopted by innovators having patent rights over products to renew them by bringing in some minor changes.

Story continues below Advertisement

But some companies are struggling with the evergreening law, he said, adding that in total the IPR is a good policy."No company is taking up patent issues with the WTO as they are looking to sort out the issue through treaties," he said, adding that US companies particularly have a problem with patents here.GP Srivastava, Chief Advisor, Assocham, welcomed the move by the government. He said making IPR come under the DIPP is a good move. Vaidheesh of GSK Pharma said it is a well-articulated policy. He said fundamentally it is a big shift. "The only issue is how the policy is going ot be implemented."

Rajeshwari Hariharan of Rajeshwari & Associates said the government may want to consider ways to promote innovation for new users in future. But she said the policy lays down a framework for a utility model that exists in other countries.